Pay in 4 interest-free payments of $20.00 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
InChiKey: JGQPZPLJOBHHBK-UFXYQILXSA-N
PubMed Central PMCID: PMC4466038
KDR (VEGFR2)
is a novel inhibitor of the interaction between ß-catenin and T cell factor 4 (Tcf4)
It was first approved by the FDA on 15 September 2000
Perifosine Size:2mg solid InChiKey: JGQPZPLJOBHHBK-UFXYQILXSA-NPerifosine is an orally active alkyl phosphocholine compound with potential antineoplastic activity. Targeting cellular membranes, perifosine modulates membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth. This agent also inhibits the anti apoptotic mitogen activated protein kinase (MAPK) pathway and modulates the balance between
US$ 19.15
US$ 169.95